Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Gene Therapy Aims to Curtail Retinal Degeneration in RP
In a landmark study that promises new hope for nearly 1.5 million people worldwide suffering from retinitis pigmentosa (RP), scientists at Columbia University Vagelos College of Physicians and Surgeons are pioneering a gene therapy that could potentially treat RP patients…
Nicox Reveals Successful Phase 3 Glaucoma Eye Drop
Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
2023 Recap: Top 15 Ophthalmic Medical Devices
In a groundbreaking year for ophthalmic advancements, 2023 has witnessed the launch of cutting-edge medical devices that promise to reshape the landscape of eye care. From augmented reality headsets to innovative surgical systems, the field is experiencing a wave of…
GRF Allocates $2.5M Grant for Glaucoma Research
The Glaucoma Research Foundation (GRF) announced an unprecedented $2.5 million allocation in annual research grants, marking the most significant investment in its 46-year history dedicated to pioneering efforts towards treating glaucoma and vision loss. Understanding Glaucoma and Its Impact Glaucoma…
MediPrint Finalizes Glaucoma Contact Lens Study
MediPrint Ophthalmics has successfully completed its SIGHT-2 phase 2b study, showcasing the efficacy of its innovative product, LL-BMT1, against a control group using bimatoprost 0.01% ophthalmic solution. LL-BMT1, a preservative-free, weekly drug-eluting contact lens, utilizes the company’s 3D printing technology,…
Vital Tears Names Joseph Tauber, MD as CMO
Vital Tears, known for its innovative autologous serum tears, is excited to announce the appointment of Joseph Tauber, MD, to the role of Chief Medical Officer (CMO). This strategic addition aims to fortify the company’s commitment to leading-edge research, physician…
Pediatric Cataract Surgery Restores Vision for Infant
Nethradhama Super Speciality Eye Hospitals achieved a remarkable feat in pediatric eye care with the successful completion of a high-risk paediatric cataract surgery on an 8-month-old baby in Bangalore. Led by Dr. Sri Ganesh, a distinguished eye surgeon and the…
Glaukos’ iDose TR Hits the Commercial Market
Glaukos Corporation’s iDose TR, using Celanese’s VitalDose EVA (Ethylene Vinyl Acetate), to provide sustained drug release for the treatment of glaucoma has officially entered the commercial market. Having received FDA approval in December, iDose TR represents a notable departure from…